The global Biologics Safety Testing Market is experiencing strong growth as pharmaceutical and biotechnology companies increasingly prioritize product safety, quality, and regulatory compliance throughout the biologics development and manufacturing lifecycle. According to MarketsandMarkets™, the market is projected to grow from approximately USD 5.57 billion in 2026 to USD 9.66 billion by 2031, registering a CAGR of 11.6% during the forecast period.
Download PDF Brochure:
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=34624144
Browse 260 market data Tables and 60 Figures spread through 270 Pages and in-depth TOC on “Biologics Safety Testing Market – Global Forecast to 2031”
Biologics Safety Testing Market Size & Forecast
- Market Size Available for Years: 2025–2031
- 2026 Market Size: USD 5.57 billion
- 2031 Projected Market Size: USD 9.66 billion
- CAGR (2026–2031): 11.6%
Biologics Safety Testing Market Trends & Insights
The biologics safety testing market is being driven by the rapid expansion of biologic drug pipelines, increasing development of biosimilars, growing adoption of advanced therapeutic modalities, and stringent regulatory requirements.
The emergence of cell and gene therapies, mRNA products, monoclonal antibodies, therapeutic proteins, and other complex biologics has increased the need for comprehensive testing throughout product development and manufacturing.
Key market insights include:
- By offering, the product segment accounted for the largest share of 41.9% in 2025.
- Pharmaceutical and biotechnology companies dominated the biologics safety testing products market in 2025, accounting for 56.0%.
- North America accounted for 43% of the global market in 2025, making it the largest regional market.
- Within the services market, vaccine safety testing is expected to be the fastest-growing application segment during the forecast period.
Growing Demand for Biologics Safety Testing
The rapid expansion of the global biologics industry is one of the most important factors supporting the growth of the biologics safety testing market.
Unlike many conventional small-molecule drugs, biologics are complex products that can be affected by manufacturing processes, raw materials, contamination risks, and other variables. As biologics pipelines become increasingly diverse, pharmaceutical and biotechnology companies require robust safety testing strategies to support product quality and regulatory compliance.
The increasing development of cell and gene therapies and mRNA-based products is creating additional testing requirements. These advanced modalities often involve complex manufacturing processes and specialized analytical considerations, increasing demand for sophisticated safety testing technologies and services.
At the same time, the expanding biosimilar pipeline is encouraging manufacturers to strengthen testing capabilities and demonstrate product quality and safety.
Services Segment Holds a Leading Position
By offering, the global biologics safety testing market is segmented into products and services. The services segment accounted for the largest share of the market in 2025.
Increasing outsourcing to contract research organizations (CROs) and contract development and manufacturing organizations (CDMOs) is a major factor supporting the segment. Many pharmaceutical and biotechnology companies rely on external providers to access specialized testing capabilities, regulatory expertise, advanced technologies, and established laboratory infrastructure.
The increasing complexity of biologics development is also encouraging companies to seek end-to-end testing support covering different stages of development and manufacturing.
Service providers can support activities ranging from early-stage development and characterization to manufacturing-related testing and regulatory documentation. The growing production of biologics and advanced therapies is expected to further strengthen demand for specialized safety testing services.
Request Sample Pages:
https://www.marketsandmarkets.com/requestsampleNew.asp?id=34624144
Vaccine Safety Testing to Witness Rapid Growth
By application, the biologics safety testing services market includes monoclonal antibodies and therapeutic proteins safety testing, vaccine safety testing, cellular and gene therapy safety testing, blood and blood products safety testing, and other applications.
Among these, the vaccine safety testing segment is projected to register the fastest growth during the forecast period.
The expansion of immunization programs, increasing vaccine production, and continued development of new and improved vaccines are creating sustained demand for safety testing.
Vaccine manufacturers must meet stringent quality and safety requirements, including testing associated with manufacturing processes and batch release. As global vaccination initiatives expand and new vaccine technologies emerge, demand for comprehensive safety testing solutions is expected to increase.
The continued development of innovative vaccine platforms also creates opportunities for testing providers to expand their capabilities and address increasingly complex product requirements.
Advanced Therapies Create New Market Opportunities
The growth of cell and gene therapies represents an important opportunity for biologics safety testing providers.
These therapies involve complex biological materials and specialized manufacturing processes, creating demand for advanced testing approaches capable of addressing contamination, microbial safety, viral safety, and other critical quality considerations.
Similarly, the development of mRNA therapeutics and vaccines is expanding the range of biologic products entering development and commercial manufacturing.
As pharmaceutical companies diversify their pipelines beyond conventional biologics, testing providers are expected to invest in new technologies, analytical capabilities, and specialized services to address the requirements of emerging modalities.
Regulatory Requirements Drive Testing Demand
Stringent and evolving regulatory requirements remain a significant driver of the biologics safety testing market.
Regulatory agencies require manufacturers to demonstrate the safety, quality, consistency, and reliability of biologic products before commercialization. As biologics become more complex, testing requirements are also evolving to address new manufacturing technologies and therapeutic modalities.
Regulatory compliance creates demand for comprehensive safety testing throughout the product lifecycle. Pharmaceutical companies must therefore maintain robust testing strategies to identify potential safety risks, support quality assurance, and meet regulatory expectations.
The increasing emphasis on quality-by-design principles and process control is expected to further strengthen demand for specialized testing services.
North America Leads the Global Market
North America accounted for 43% of the global biologics safety testing market in 2025, making it the largest regional market.
The region benefits from a high concentration of pharmaceutical and biotechnology companies, advanced research infrastructure, strong clinical development capabilities, and established regulatory oversight.
The US, in particular, represents an important center for biologics innovation and manufacturing. The presence of a large biologics pipeline, increasing adoption of cell and gene therapies, and continued clinical research activity are supporting demand for safety testing solutions.
Strong public and private investment in life sciences research is also contributing to market development. Furthermore, widespread outsourcing to CROs and CDMOs is creating opportunities for specialized testing providers.
Outsourcing Strengthens the Competitive Landscape
Outsourcing is becoming increasingly important in biologics safety testing as companies seek access to specialized expertise, advanced laboratory infrastructure, and regulatory support.
CROs and CDMOs can provide scalable testing capabilities without requiring pharmaceutical companies to make extensive investments in internal facilities and specialized personnel.
This trend is particularly relevant for small and emerging biotechnology companies developing complex biologics and advanced therapies. By outsourcing safety testing activities, these companies can focus internal resources on drug discovery and development while leveraging external technical expertise.
Future Outlook for the Biologics Safety Testing Market
The future of the biologics safety testing market will be shaped by the continued expansion of biologics pipelines and the emergence of increasingly sophisticated therapeutic platforms.
The convergence of advanced biologics, cell and gene therapies, mRNA products, biosimilars, automation, digital technologies, and increasingly sophisticated analytical methods is expected to create new opportunities for testing providers.
Companies are likely to focus on improving testing efficiency, shortening turnaround times, expanding testing portfolios, and developing capabilities specifically designed for emerging therapeutic modalities.
The growing role of CROs and CDMOs is also expected to reshape the market as pharmaceutical companies increasingly adopt flexible outsourcing models.
Competitive Landscape
The biologics safety testing market features a diverse group of global pharmaceutical services, life sciences, analytical testing, and biotechnology companies.
Top companies in the market include:
- Thermo Fisher Scientific Inc. (US)
- Merck KGaA (Germany)
- Lonza (Switzerland)
- FUJIFILM Corporation (Japan)
- Sartorius AG (Germany)
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Charles River Laboratories (US)
- bioMérieux (France)
- Maravai LifeSciences (US)
- WuXi AppTec (China)
- SGS Société Générale de Surveillance SA (Switzerland)
- Sotera Health (US)
- Samsung Biologics (South Korea)
- GenScript (US)
- Agilent Technologies, Inc. (US)
- Syngene International Limited (India)
- Eurofins Scientific (Luxembourg)
- Laboratory Corporation of America Holdings (US)
- Bio-Rad Laboratories, Inc. (US)
- QIAGEN (Netherlands)
These companies are focusing on expanding testing capabilities, strengthening laboratory infrastructure, developing advanced analytical technologies, and supporting pharmaceutical and biotechnology customers throughout the biologics development and manufacturing lifecycle.
Key Opportunities in Emerging Biologics
The expansion of next-generation therapeutics is expected to provide significant opportunities for biologics safety testing providers. Cell and gene therapies, mRNA products, biosimilars, and other complex biologics require specialized testing strategies that can address their unique safety and manufacturing characteristics.
As these therapies move from research and development into clinical and commercial stages, demand for validated and scalable safety testing solutions is expected to increase.
At the same time, growing biologics manufacturing capacity in emerging markets is likely to create additional opportunities for regional testing providers and global companies expanding their geographic footprint.
Conclusion
The global Biologics Safety Testing Market is projected to grow from USD 5.57 billion in 2026 to USD 9.66 billion by 2031, at a CAGR of 11.6%. The market is benefiting from the expanding biologics pipeline, growing adoption of cell and gene therapies and mRNA products, increasing biosimilar development, stringent regulatory requirements, and rising outsourcing to CROs and CDMOs.
While North America currently holds the largest market share, opportunities are expanding globally as biologics development and manufacturing capabilities continue to grow.
The increasing complexity of advanced therapies will make comprehensive safety testing an increasingly essential component of pharmaceutical development and manufacturing. As testing technologies evolve alongside emerging therapeutic modalities, the biologics safety testing market is expected to remain an important and rapidly developing segment of the global life sciences industry.
Inquire Before Buying:
https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=34624144
